Pharma giant Roche expands AI infrastructure via Nvidia partnership
Original framing: “Roche ramps up AI computing capacity with Nvidia chip expansion - Reuters” — Reuters (via Google News)
While AI can accelerate drug discovery, the scientific community is increasingly concerned about the lack of transparency and reproducibility in proprietary AI models. The use of closed-source systems like Nvidia’s chips may hinder peer review and scientific validation, which are essential for ensuring the safety and efficacy of new drugs.
Roche’s expansion of AI computing with Nvidia reflects a broader trend of pharmaceutical consolidation and tech dependency that marginalizes alternative knowledge systems and community voices.
While AI has the potential to accelerate drug discovery, its current application is shaped by corporate interests and closed systems that limit transparency and equity. Historical patterns of pharmaceutical monopolization and the exclusion of Indigenous and local knowledge highlight the need for open-source, participatory models. Cross-culturally, open AI initiatives in the Global South offer a counter-narrative to the Roche-Nvidia model. To move forward, systemic solutions must include global governance, inclusive design, and the integration of diverse epistemologies. This requires not only technological innovation but also a reimagining of power structures in health and science.